Literature DB >> 18923807

LRRK2 P755L variant in sporadic Parkinson's disease.

Hiroyuki Tomiyama1, Ikuko Mizuta2,3, Yuanzhe Li1, Manabu Funayama4, Hiroyo Yoshino4, Lin Li1, Miho Murata3,5, Mitsutoshi Yamamoto3,6, Shin-Ichiro Kubo1, Yoshikuni Mizuno4, Tatsushi Toda2,3, Nobutaka Hattori7,8.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder of unknown etiology with probable involvement of genetic-environmental factors. The majority of PD cases (approximately 90-95%) are sporadic, while familial cases account for approximately 5-10% of PD. In a recent report, a heterozygous LRRK2 P755L mutation within LRRK2 exon 19 was found in 2% of Chinese sporadic PD patients and in 0% of normal controls or Caucasians, suggesting that the mutation is disease-associated with ethnic specificity. To further evaluate the role of LRRK2 P755L variant in sporadic PD, we performed direct sequencing of LRRK2 exon 19 in 501 Japanese sporadic PD patients (male 249, female 252, aged 28-92 years, mean 65.0 years) and 583 controls of the Japanese general population as an extended association study. In this group, we found six patients (6/501 = 1.2%) and eight controls of the general population (8/583 = 1.6%) with a heterozygous P755L variant (P = 0.80, chi(2) = 0.064). No other variants were found in exon 19. Together with previous reports, our extended case-controlled study of large sample size suggests that LRRK2 P755L is a non-disease-associated polymorphism in PD patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18923807     DOI: 10.1007/s10038-008-0336-5

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  17 in total

1.  LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs.

Authors:  Suzanne Lesage; Alexandra Dürr; Meriem Tazir; Ebba Lohmann; Anne-Louise Leutenegger; Sabine Janin; Pierre Pollak; Alexis Brice
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

2.  The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence.

Authors:  E K Tan; Y Zhao; L Skipper; M G Tan; A Di Fonzo; L Sun; S Fook-Chong; S Tang; E Chua; Y Yuen; L Tan; R Pavanni; M C Wong; P Kolatkar; C S Lu; V Bonifati; J J Liu
Journal:  Hum Genet       Date:  2006-09-30       Impact factor: 4.132

3.  Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia.

Authors:  Matthew J Farrer; Jeremy T Stone; Chin-Hsien Lin; Justus C Dächsel; Mary M Hulihan; Kristoffer Haugarvoll; Owen A Ross; Ruey-Meei Wu
Journal:  Parkinsonism Relat Disord       Date:  2007-01-10       Impact factor: 4.891

4.  Lrrk2 pathogenic substitutions in Parkinson's disease.

Authors:  Ignacio F Mata; Jennifer M Kachergus; Julie P Taylor; Sarah Lincoln; Jan Aasly; Timothy Lynch; Mary M Hulihan; Stephanie A Cobb; Ruey-Meei Wu; Chin-Song Lu; Carlos Lahoz; Zbigniew K Wszolek; Matthew J Farrer
Journal:  Neurogenetics       Date:  2005-09-17       Impact factor: 2.660

5.  Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.

Authors:  William C Nichols; Nathan Pankratz; Dena Hernandez; Coro Paisán-Ruíz; Shushant Jain; Cheryl A Halter; Veronika E Michaels; Terry Reed; Alice Rudolph; Clifford W Shults; Andrew Singleton; Tatiana Foroud
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

6.  Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population.

Authors:  Manabu Funayama; Yuanzhe Li; Hiroyuki Tomiyama; Hiroyo Yoshino; Yoko Imamichi; Mitsutoshi Yamamoto; Miho Murata; Tatsushi Toda; Yoshikuni Mizuno; Nobutaka Hattori
Journal:  Neuroreport       Date:  2007-02-12       Impact factor: 1.837

7.  A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1.

Authors:  Manabu Funayama; Kazuko Hasegawa; Hisayuki Kowa; Masaaki Saito; Shoji Tsuji; Fumiya Obata
Journal:  Ann Neurol       Date:  2002-03       Impact factor: 10.422

8.  Pathogenicity of LRRK2 P755L variant in Parkinson's disease.

Authors:  Eng-King Tan; Hui-Qin Lim; Yih Yuen; Yi Zhao
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

9.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

10.  A common LRRK2 mutation in idiopathic Parkinson's disease.

Authors:  William P Gilks; Patrick M Abou-Sleiman; Sonia Gandhi; Shushant Jain; Andrew Singleton; Andrew J Lees; Karen Shaw; Kailash P Bhatia; Vincenzo Bonifati; Niall P Quinn; John Lynch; Daniel G Healy; Janice L Holton; Tamas Revesz; Nicholas W Wood
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

View more
  10 in total

1.  Measuring the activity of leucine-rich repeat kinase 2: a kinase involved in Parkinson's disease.

Authors:  Byoung Dae Lee; Xiaojie Li; Ted M Dawson; Valina L Dawson
Journal:  Methods Mol Biol       Date:  2012

2.  NMR determination of pKa values in α-synuclein.

Authors:  Robyn L Croke; Sharadrao M Patil; Jason Quevreaux; Debra A Kendall; Andrei T Alexandrescu
Journal:  Protein Sci       Date:  2010-12-13       Impact factor: 6.725

Review 3.  Gene-environment interactions: key to unraveling the mystery of Parkinson's disease.

Authors:  Hui-Ming Gao; Jau-Shyong Hong
Journal:  Prog Neurobiol       Date:  2011-03-23       Impact factor: 11.685

Review 4.  Targeting Mitochondria as a Therapeutic Approach for Parkinson's Disease.

Authors:  Maryam Abrishamdar; Maryam Sadat Jalali; Yaghoob Farbood
Journal:  Cell Mol Neurobiol       Date:  2022-08-11       Impact factor: 4.231

5.  Neuroprotective Effects of Cranberry Juice Treatment in a Rat Model of Parkinson's Disease.

Authors:  Łukasz Witucki; Monika Kurpik; Hieronim Jakubowski; Michał Szulc; Przemysław Łukasz Mikołajczak; Jadwiga Jodynis-Liebert; Małgorzata Kujawska
Journal:  Nutrients       Date:  2022-05-11       Impact factor: 6.706

Review 6.  Preconditioning as a potential strategy for the prevention of Parkinson's disease.

Authors:  Mojtaba Golpich; Behrouz Rahmani; Norlinah Mohamed Ibrahim; Leila Dargahi; Zahurin Mohamed; Azman Ali Raymond; Abolhassan Ahmadiani
Journal:  Mol Neurobiol       Date:  2014-04-03       Impact factor: 5.590

Review 7.  Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.

Authors:  Karen Nuytemans; Jessie Theuns; Marc Cruts; Christine Van Broeckhoven
Journal:  Hum Mutat       Date:  2010-07       Impact factor: 4.878

8.  Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson's disease.

Authors:  Vinicius M Fava; Yong Zhong Xu; Guillaume Lettre; Nguyen Van Thuc; Marianna Orlova; Vu Hong Thai; Shao Tao; Nathalie Croteau; Mohamed A Eldeeb; Emma J MacDougall; Geison Cambri; Ramanuj Lahiri; Linda Adams; Edward A Fon; Jean-François Trempe; Aurélie Cobat; Alexandre Alcaïs; Laurent Abel; Erwin Schurr
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-15       Impact factor: 11.205

9.  Genomic Characteristics of Genetic Creutzfeldt-Jakob Disease Patients with V180I Mutation and Associations with Other Neurodegenerative Disorders.

Authors:  Sol Moe Lee; Myungguen Chung; Jae Wook Hyeon; Seok Won Jeong; Young Ran Ju; Heebal Kim; Jeongmin Lee; SangYun Kim; Seong Soo A An; Sung Beom Cho; Yeong Seon Lee; Su Yeon Kim
Journal:  PLoS One       Date:  2016-06-24       Impact factor: 3.240

Review 10.  LRRK2 at the Crossroad of Aging and Parkinson's Disease.

Authors:  Eun-Mi Hur; Byoung Dae Lee
Journal:  Genes (Basel)       Date:  2021-03-29       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.